NEW YORK (AP) The Food and Drugs Administration on Monday approved two new penile-enhancing vaccines for patients with a condition called retroviral retinopathy.
The drugs, called nevirax and fosamprenavir, are designed to help patients with retrovirus infections who have been treated with the standard vaccines.
They are not intended for patients who have had previous infections, and have not been tested for HIV.
Retroviral retina is a rare genetic disorder that occurs in up to 30 percent of HIV-positive people, and affects up to 20 percent of penile tumours, according to the FDA.
In the study, published in the journal JAMA Internal Medicine, the drugs helped patients who had already had the retroviruses treated for cancer, but not HIV, regain the ability to produce testosterone.
The FDA said it expects more approval for the two drugs in the future.
The companies, Novartis and GlaxoSmithKline, have been developing the drugs, which are being marketed as the nevirab and fodavir vaccines.
Novartys spokeswoman Mary-Claire Taylor said in an email that the company has been evaluating the vaccine as well as the drug.
Glaxos, which has been producing the standard vaccine since 2004, did not immediately respond to an email seeking comment.
A third company, Glaxovax, said it was not involved in the study.